COVID-19 – Wales – Shielding update and Q&A

Filmed on 23/06/2020. We are joined by Dr Steven Knapper, Senior Lecturer and Honorary Consultant Haematologist at the University Hospital Wales and Dr Nilima Parry - Jones consultant haematologist and MDT Chair Aneurin Bevan University Health Board.

23 June 2020

VIDEO RECORDED LIVE on 23/6/2020.

INFORMATION CORRECT AS OF THIS DATE.

Welcome to our 3rd set of webinars on shielding. This time we are talking specifically about the guidance for patients in Wales. We are joined by Dr Steven Knapper, Senior Lecturer and Honorary Consultant Haematologist at the University Hospital Wales and Dr Nilima Parry – Jones consultant haematologist and MDT Chair Aneurin Bevan University Health Board.

We will update and summarise Wales government shielding guidance and support provision; what this now means to patients and their families as shielding evolves.

Any questions, please email advocacy@leukaemiacare.org.uk.

Outcomes of essential thrombocythaemia (ET)

Essential thrombocythaemia (ET) is a rare, slow-growing blood cancer. It results in too many platelets in your blood, leading to blood clots, bleeding and other symptoms. Blood clots pose the main risk to your health when you have ET. Find out how your haematology team assess your risk of blood clots, and how outcomes vary according to your ET risk group.